Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Thiem VD, Anh DD, Ha VH, Van Thom N, Thang TC, Mateus J, Carreño JM, Raghunandan R, Huong NM, Mercer LD, Flores J, Escarrega EA, Raskin A, Thai DH, Van Be L, Sette A, Innis BL, Krammer F, Weiskopf D.
Thiem VD, et al. Among authors: thai dh.
Vaccine. 2025 Jan 12;44:126542. doi: 10.1016/j.vaccine.2024.126542. Epub 2024 Nov 29.
Vaccine. 2025.
PMID: 39615342
Free PMC article.
Clinical Trial.